Anzeige
Mehr »
Samstag, 30.08.2025 - Börsentäglich über 12.000 News
SuperBuzz: Die KI-Aktie, die man sich jetzt zum Ende des Sommers nicht entgehen lassen darf
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PJ5B | ISIN: KYG4672N1198 | Ticker-Symbol: H7T2
Frankfurt
29.08.25 | 08:06
2,380 Euro
-4,03 % -0,100
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
HUTCHMED CHINA LIMITED Chart 1 Jahr
5-Tage-Chart
HUTCHMED CHINA LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
2,4002,80013:04

Aktuelle News zur HUTCHMED Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiHutchmed China CFO Cheng is interim CEO as CEO Su takes health leave1
DiHUTCHMED ernennt CFO Johnny Cheng zum kommissarischen CEO3
DiHUTCHMED names CFO Johnny Cheng as acting CEO amid CEO's leave2
DiHutchmed China Ltd - Directorate Change-
MoHUTCHMED (00013): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS-
MoHUTCHMED CEO takes leave of absence; CFO Johnny Cheng appointed acting CEO1
MoHUTCHMED China CEO Weiguo Su To Take Leave Of Absence; Names Johnny Cheng Acting CEO279LONDON (dpa-AFX) - HUTCHMED (China) Limited (HUTCHMED) (HCM, HCM.L) announces that Weiguo Su will take a leave of absence from his duties as Chief Executive Officer due to health reasons. Accordingly...
► Artikel lesen
HUTCHMED Aktie jetzt für 0€ handeln
MoHUTCHMED (China) Limited: HUTCHMED Announces Appointment of Acting Chief Executive Officer1.123HONG KONG and SHANGHAI and FLORHAM PARK, N.J, Aug. 25, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:?HCM; HKEX:?13) today announces that Dr Weiguo Su, an Executive Director...
► Artikel lesen
MoHUTCHMED (00013): HUTCHMED ANNOUNCES APPOINTMENT OF ACTING CHIEF EXECUTIVE OFFICER4
22.08.HUTCHMED (00013): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM: NOTICE OF PUBLICATION OF THE 2025 INTERIM REPORT-
22.08.HUTCHMED (00013): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM: NOTICE OF PUBLICATION OF THE 2025 INTERIM REPORT-
22.08.HUTCHMED (00013): 2025 INTERIM REPORT-
20.08.HUTCHMED Ltd - 6-K, Report of foreign issuer2
20.08.Hutchmed enrols last patient in phase 3 lung cancer trial3
20.08.Hutchmed completes enrollment in lung cancer combination therapy trial1
20.08.Hutchmed China Ltd - HUTCHMED Completes Enrollment of Phase III Trial-
20.08.HUTCHMED (China) Limited: HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS and TAGRISSO Combination as a First-Line Therapy for Certain Lung Cancer Patients in China152HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:?HCM; HKEX:?13) today announces the completion of patient enrollment...
► Artikel lesen
20.08.HUTCHMED (00013): VOLUNTARY ANNOUNCEMENT - HUTCHMED COMPLETES PATIENT ENROLLMENT OF SANOVO PHASE III TRIAL OF ORPATHYS AND TAGRISSO COMBINATION AS A FIRST-LINE ...1
12.08.Daiwa Drops HUTCHMED's TP to HKD30 w/Lower Sales Forecasts2
12.08.CMBI Drops HUTCHMED TP to $31.39, Expects Domestic Sales to Face Pressure1
Weiter >>
181 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1